MedTrace Logo

A Dose-finding Study of ASP4070

NCT03101267 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-11-26

Study results available
· View outcomes & findings →

Summary

The objective of this study was to evaluate the efficacy, safety, and dose-response of ASP4070 vaccinated in patients with cedar pollinosis.

Conditions

  • Rhinitis, Allergic, Seasonal

Interventions

DRUG

ASP4070

Intradermal vaccination at 2-week intervals

DRUG

Placebo

Intradermal vaccination at 2-week intervals

Sponsors & Collaborators

  • Immunomic Therapeutics, Inc.

    collaborator INDUSTRY

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Medical Director · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-13
Primary Completion
2018-01-26
Completion
2018-10-27
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03101267 on ClinicalTrials.gov